CVS looks to 2023 after opioids settlement, Medicare rating decline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
'Several De-Risking Events Positive' for CVS Health (CVS) - Mizuho
November 2, 2022 12:58 PM EDTMizuho Securities analyst Ann Hynes reiterated a Buy rating and $120.00 price target on CVS Health (NYSE: CVS) following Q3 results as several de-risking events are positive for the stock.
The analyst commented, "CVS announced 1) good Q3:22 earnings, 2) provided 2023 initial 2023 EPS guidance of -3.5%... More
